title: Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects.
abstract: OBJECTIVE
  Recently, lipoprotein(a) [Lp(a)] has been identified as a major risk factor for coronary heart disease. There are few data available on the influence of metabolic control on plasma Lp(a) concentrations in subjects with insulin-dependent diabetes mellitus (IDDM), a group at high risk for coronary heart disease.
  
  
  METHODS
  We examined the effects of improved metabolic control on plasma lipid and lipoproteins and Lp(a) concentrations in 12 subjects before and after 21 days of tight metabolic control.
  
  
  RESULTS
  Glycosylated hemoglobin declined from 8.4 to 6.9% (P less than 0.001), and Lp(a) declined from 29.7 to 27.1 mg/dl (P = 0.022). There were no significant differences in total, low-density lipoprotein, or high-density lipoprotein cholesterol, although the decline in triglyceride concentrations were borderline statistically significant. The distribution of apolipoprotein(a) isoforms in IDDM patients was not unusual, and the apolipoprotein(a) isoform phenotypes did not change with improved metabolic control. Lp(a) concentrations were also significantly higher than in a population-based control group of nondiabetic subjects from the San Antonio Heart Study.
  
  
  CONCLUSIONS
  Although the number of subjects was small and the degree of improvement in metabolic control was modest, the results suggest that improved metabolic control may decrease the risk of coronary heart disease mediated by Lp(a) in IDDM.
authors.affiliation: Department of Medicine, University of Texas Health Science Center, San Antonio 78284.
authors.forename: S M
authors.initials: SM
authors.lastname: Haffner
authors.forename: K R
authors.initials: KR
authors.lastname: Tuttle
authors.forename: D L
authors.initials: DL
authors.lastname: Rainwater
mesh_terms: D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D053241:Apoprotein(a); D001786:Blood Glucose / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000097:blood; D017270:Lipoprotein(a); D008074:Lipoproteins / Q000097:blood*; D008297:Male
chemical_list: D001053:Apolipoproteins; D053241:Apoprotein(a); D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007328:Insulin; D017270:Lipoprotein(a); D008074:Lipoproteins